表 2.
ICIs对MET突变NSCLC的疗效
Efficacy of ICIs for MET-mutated NSCLC
| Study | Year | Mutation | Subtype | Treatment | ICI line | Total No. | ORR | DCR | mPFS (mon) |
mOS (mon) |
| NA: not available. | ||||||||||
| Dudnik, et al[10] | 2018 | MET | MET amplification | PD-(L)1 mAb | 2 | 4 | 25% | - | 4.9 | NR |
| 2018 | MET | MET 14 skipping | PD-(L)1 mAb | 2 | 8 | 13% | - | 4.0 | NR | |
| Mazieres, et al[13] | 2019 | MET | NA | 94% PD-1 mAb | 3 | 36 | 16% | 50% | 3.4 | 18.4 |
| Guisier, et al[16] | 2020 | MET | MET 14 skipping | PD-(L)1 mAb | 2 | 30 | 36% | 71% | 4.9 | 13.4 |
| Sabari, et al[19] | 2018 | MET | MET 14 skipping | 92% PD-(L)1 mAb | 2 | 24 | 17% | 46% | 1.9 | 18.2 |